SINOPHARM GROUP 1/5/

SINOPHARM GROUP 1/5/ Depository Receipt · US82937K1016 · A2P3LX (XFRA) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of SINOPHARM GROUP 1/5/
No Price
01.05.2026 19:57
Current Prices from SINOPHARM GROUP 1/5/
ExchangeTickerCurrencyLast TradePriceDaily Change
OTC: UTC
UTC
SHTDY
USD
01.05.2026 19:57
11,88 USD
0,04 USD
+0,34 %
Company Profile for SINOPHARM GROUP 1/5/ Depository Receipt
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Company Data

Name SINOPHARM GROUP 1/5/
Company Sinopharm Group Co. Ltd.
Website https://www.sinopharmgroup.com.cn
Primary Exchange XFRA Frankfurt
WKN A2P3LX
ISIN US82937K1016
Asset Class Depository Receipt
Sector Healthcare
Industry Medical - Distribution
CEO Wanyong Lian
Market Capitalization 7 Mrd.
Country China
Currency EUR
Employees 108,2 T
Address Sinopharm Group Building, 200023 Shanghai
IPO Date 2016-08-25
Dividends from 'SINOPHARM GROUP 1/5/'
Ex-Date Dividend per Share
17.06.2025 0,47 USD
18.06.2024 0,60 USD
15.06.2023 0,60 USD
24.06.2022 0,59 USD
14.06.2021 0,43 USD
12.06.2020 0,33 USD
01.07.2019 0,35 USD
02.07.2018 0,36 USD
29.06.2017 0,29 USD
18.08.2016 0,34 USD

Ticker Symbols

Name Symbol
Over The Counter SHTDY
Frankfurt X2S1.F
More Shares
Investors who hold SINOPHARM GROUP 1/5/ also have the following shares in their portfolio:
Choksi Imaging Limited
Choksi Imaging Limited Share
Invesco MSCI Sustainable Future ETF
Invesco MSCI Sustainable Future ETF ETF